An interventional study of Reminders to the assistant clinicians of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment community-acquired pneumonia in Community-acquired Pneumonia, sponsored by Instituto de Investigacion Sanitaria La Fe. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-01-11.
Sponsored by Instituto de Investigacion Sanitaria La Fe · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Community-Acquired Pneumonia with a site in Spain — 5 open to participants now, 6 under way, 3 of them phase 3. Community-Acquired Pneumonia · Spain.
Among the 32 studies in Community-Acquired Pneumonia with a site in Spain, this one is the 3rd largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2024, is one of 5 with no phase, and was the 29th registered.
325 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.
Browse Community-Acquired Pneumonia studies →5 of the 32 studies in Community-Acquired Pneumonia with a site in Spain are open now. Recruiting first, the newest first:
Biotest · Sites in Spain, United States, Argentina and 15 more countries
Ages 18+
University of Oxford · Sites in Spain, Belgium, Estonia and 13 more countries
Ages 0+
UMC Utrecht · Sites in Spain, United States, Australia and 26 more countries
Ages 28 days+
Joan Sabater-Riera · Sites in Spain, Croatia, France and 3 more countries
Ages 65+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 10 · Phase 4 4
First in 2001; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 246 across 196 interventional studies indexed under Community-Acquired Pneumonia.
Median enrollment 314 across the 23 interventional studies, 500 across the 9 observational. Of the 21 that completed or were terminated, 4 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 32 have an industry lead sponsor. The 10 most frequent:
Instituto de Investigacion Sanitaria La Fe is the lead sponsor of 58 studies on the registry; 12 are open to participants now.
Instituto de Investigacion Sanitaria La Fe has 1 study filed under Community-Acquired Pneumonia — fewer than ten, so there is no comparison to draw.
2 of the studies in Community-Acquired Pneumonia with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07070284Joan Sabater-RieraESCAPE10: Epidemiology, Risk Factors, and Outcomes of Severe Community-acquired Pneumonia in Elderly Patients Acquired Pneumonia in Elderly Patients | 2026-11-30 |
| NCT07178483Hospital Universitari de BellvitgeEvaluation of Physical Capacity and Energy Requirements in Patients With Hypoxemic Acute Respiratory Failure | 2027-03-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 32 studies in Community-Acquired Pneumonia with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
International and national clinical guidelines recommend short antibiotic regimens in patients with non-severe community-acquired pneumonia (CAP) who have reached clinical stability. However, adherence to these recommendations remains unclear. The goals of this quasi-experimental trial are: 1) to assess adherence to clinical guidelines in relation to the duration of antibiotic treatment in patients hospitalized for non-severe CAP who have reached clinical stability; 2) increase adherence to clinical guidelines and reduce the use of antibiotics in patients hospitalized for non-severe CAP who have achieved clinical stability after at least 5 days of antibiotic treatment.
To this end, a multicenter prospective study will be carried out over 2 years and divided into 2 phases: i) during the first year (observational phase), patients with CAP hospitalized in the participating centers will be recorded to assess objective 1; ii) to achieve objective 2, at the beginning of the second year (quasi-experimental trial) the centers will be randomized into 2 groups of hospitals, one of them a control group and the other an intervention group. The intervention will consist in automatic reminders through pop-up windows in the computerized prescription software, reminding the clinician responsible for each patient of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment in patients with clinical stability.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients allocated in hospitals randomized to non-interventional arm. Observational analysis of patients treated by clinicians with standard of care.
Patients allocated in hospitals randomized to interventional arm. Intervention: automatic reminders through pop-up windows in the computerized prescription software, reminding the clinician responsible for each patient of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment in patients with clinical stability
Behavioral: Reminders to the assistant clinicians of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment community-acquired pneumonia
Automatic reminders through pop-up windows in the computerized prescription software, reminding the clinician responsible for each patient of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment in patients with clinical stability
Also known as: Reminders to the clinician responsible for each patient of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment in patients with clinical stability
Duration of antibiotic treatment
Total duration in days of antibiotic treatment (including the days of outpatient antibiotic prescribed at discharge).
Time frame: 90 days
Duration of antibiotic treatment after reaching clinical stability
Duration in days of antibiotic treatment after reaching clinical stability
Time frame: 90 days
Patients treated with an adequate duration of 5±1 days
Percentage of patients treated with an adequate duration of 5±1 days
Time frame: 90 days
Patients admitted to the ICU after the 5th day
Percentage of patients admitted to the ICU after the 5th day of admission
Time frame: 90 days
Mortality
Percentage of patients who died during the study
Time frame: 90 days
Readmission
Percentage of patients who are readmitted after hospital discharge
Time frame: 90 days
Reintroduction of antibiotic treatment
Percentage of patients with reintroduction of antibiotic treatment
Time frame: 90 days
Length of hospital stay
Length of hospital stay in days
Time frame: 90 days
Adverse events related to antibiotic treatment
Percentage of patients with adverse events related to antibiotic treatment
Time frame: 90 days
Factors related to excess of antibiotic treatment
Factors o variables related to excess of antibiotic treatment
Time frame: 90 days
Plan to share: Yes
Supporting information: Study protocol, Clinical study report
No publications or documents are linked to this record.
Start is estimated for Jan 2024; primary completion for Jun 2025, 17 months later.
Of 42 non-industry interventional studies with no phase under Community-Acquired Pneumonia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 38. This study's planned 17 months is below that.
Counting every sponsor, half of 43 studies reached it within 24 months; a quarter within 14 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Community-Acquired Pneumonia →
Instituto de Investigacion Sanitaria La Fe